Page 137 - 202007

ingram Cancer Center，et al. Relatlimab clinical studies mune checkpoint-targeted antibody-ligand traps that si-
[EB/OL].[2020-01-18]. https：//clinicaltrials.gov/ct2/re- multaneously disable TGF beta enhance the efficacy of
sults?cond=Relatlimab&term=&cntry=&state=&city=& cancer immunotherapy[J]. Nat Commun，2018，9（741）：
dist=. 1-14.
[26] MARIN-ACEVEDO JA，DHOLARIA B，SOYANO AE， [38] ZHAO Y，HU J，LI R，et al. Enhanced NK cell adoptive
et al. Next generation of immune checkpoint therapy in antitumor effects against breast cancer in vitro via block-
cancer：new developments and challenges [J]. J Hematol ade of the transforming growth factor-beta signaling path-
Oncol，2018.DOI：10.1186/s13045-018-0582-8. way[J]. Onco Targets Ther，2015.DOI：10.2147/OTT.
[27] CHEVOLET I，SPEEKAERT R，SCHREUER M，et al. S82616.
Characterization of the in vivo immune network of IDO， [39] ROS XR，VERMEULEN L. Turning cold tumors hot by
tryptophan metabolism，PD-L1，and CTLA-4 in circulat- blocking TGF-β[J]. Trends Cancer，2018，4（5）：335-337.
ing immune cells in melanoma[J]. Oncoimmunology， [40] MORIKAWA M，DERYNCK R，MIYAZONO K. TGF-be-
2015. DOI：10.4161/2162402X.2014.982382. ta and the TGF-beta family：context-dependent roles in
[28] MOON YW，HAJJAR J，HWU P，et al. Targeting the in- cell and tissue physiology[J]. Cold Spring Harb Perspect
doleamine 2，3-dioxygenase pathway in cancer[J]. J Immu- Biol，2016.DOI：10.1101/cshperspect.a021873.
nother Cancer，2015，3（1）：51-60. [41] GANESH K，MASSAGUÉ J. TGF-β inhibition and immu-
[29] NISHI M，YOSHIKAWA K，HIGASHIJIMA J，et al. The notherapy：checkmate[J]. Immunity，2018，48（4）：626-
impact of indoleamine 2，3-dioxygenase（IDO）expres- 628.
sion on stage Ⅲ gastric cancer[J]. Anticancer Res，2018， [42] COURAU T，NEHAR-BELAID D，FLOREZ L，et al.
38（6）：3387-3392. TGF-beta and VEGF cooperatively control the immunotol-
[30] SAVANE IM，Main Line Health，Herlev Hospital，et al. erant tumor environment and the efficacy of cancer immu-
IDO inhibitor clinical studies[EB/OL].[2019-12-23]. notherapies[J]. JCI Insight，2016.DOI：10.1172/jci.insight.
https：//clinicaltrials.gov/ct2/results?cond=IDO&term=& 85974.
cntry=&state=&city=&dist=. [43] ARLAUCKAS SP，GARRIS CS，KOHLER RH，et al. In
[31] LIU J，XIE X，XUAN C，et al. High-density infiltration of vivo imaging reveals a tumor-associated macrophage-me-
V-domain immunoglobulin suppressor of T-cell activation diated resistance pathway in anti-PD-1 therapy[J]. Sci
up-regulated immune cells in human pancreatic cancer[J]. Transl Med，2017.DOI：10.1126/scitranslmed.aal3604.
Pancreas，2018，47（6）：725-731. [44] LIU D，JENKINS RW，SULLIVAN RJ. Mechanisms of re-
[32] LE MERCIER I，CHEN W，LINES JL，et al. VISTA regu- sistance to immune checkpoint blockade[J]. Am J Clin
lates the development of protective antitumor immunity Dermatol，2019，20（1）：41-54.
[J]. Cancer Res，2014，74（7）：1933-1944. [45] HE Y，YU H，ROZEBOOM L，et al. LAG-3 protein ex-
[33] Janssen Research & Development. A study of safety，phar- pression in non-small cell lung cancer and its relationship
macokinetics，pharmacodynamics of JNJ61610588 in par- with PD-1/PD-L1 and tumor-infiltrating lymphocytes[J]. J
ticipants with advanced cancer[EB/OL].[2020-01-18]. Thorac Oncol，2017，12（5）：814-823.
https：//clinicaltrials.gov/ct2/show/NCT02671955. [46] YUN SJ，LEE B，KOMORI K，et al. Regulation of TIM-3
[34] KONTERMANN RE，BRINKMANN U. Bispecific anti- expression in a human T cell line by tumor-conditioned
bodies[J]. Drug Discov Today，2015，20（7）：838-847. media and cyclic AMP-dependent signaling[J]. Mol Immu-
[35] KOBOLD S，PANTELYUSHIN S，RATAI F，et al. Ratio- nol，2019. DOI：10.1016/j.molimm.2018.12.006.
nale for combining bispecific T cell activating antibodies [47] ROTTE A. Combination of CTLA-4 and PD-1 blockers
with checkpoint blockade for cancer therapy[J]. Front On- for treatment of cancer[J]. J Exp Clin Cancer Res，2019，
col，2018.DOI：10.3389/fonc.2018.00285. 38（1）：255-267.
[36] LI J，ZHOU C，DONG B，et al. Single domain antibody- [48] JIA L，ZHANG Q，ZHANG R. PD-1/PD-L1 pathway
based bispecific antibody induces potent specific anti-tu- blockade works as an effective and practical therapy for
mor activity[J]. Cancer Biol Ther，2016，17（12）：1231- cancer immunotherapy[J]. Cancer Biol Med，2018，15（2）：
1239. 116-123.
[37] RAVI R，NOONAN KA，PHAM V，et al. Bifunctional im- [49] DURAISWAMY J，FREEMAN GJ，COUKOS G. Dual-

中国药房 2020年第31卷第7期 China Pharmacy 2020 Vol. 31 No. 7 ·895 ·